MetaCap

Black Diamond Therapeutics (BDTX) vs LENZ Therapeutics (LENZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Black Diamond Therapeutics (BDTX) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 65.5% versus a loss of 90.0%. Over five years, BDTX leads with a -79.3% price change compared with -95.6% for LENZ. LENZ Therapeutics is the larger company by market cap ($93.2 million vs $75.3 million), about 1.2 times the size.

Black Diamond Therapeutics converts more of its revenue into profit, with a net margin of 32.0% versus -430.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BDTX-65.53%LENZ-89.97%
+13%-41%-95%
Nov 21, 20251 yearNov 20, 2026
BDTX-81.55%LENZ-96.18%
+17%-42%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BDTX versus LENZ key metrics
MetricBDTXLENZ
Share price$1.31$2.97
Market cap$75.28M$93.16M
1-day change-5.76%-11.23%
YTD return-46.09%-81.47%
1-year return-65.53%-89.97%
5-year return-79.30%-95.57%
EPS (TTM)$-0.77$-4.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$70.00M$19.09M
Net income (latest FY)$22.37M$-82.13M
Gross margin—97.81%
Operating margin17.89%-477.46%
Net margin31.95%-430.25%
52-week high$3.97$32.13
52-week low$1.31$2.80
Distance from 52-week high-67.00%-90.77%
Analyst consensusnonenone
Avg. price target upside+663.36%+400.17%
Average volume697.70K892.30K
Shares outstanding57.47M31.42M
Employees2140
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BDTX has outperformed LENZ by 24.4 percentage points over the past year.
  • Black Diamond Therapeutics is more profitable, keeping 32.0 cents of every revenue dollar as net income versus -430.3 cents for LENZ Therapeutics.

About Black Diamond Therapeutics

BDTX stock →

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees

About LENZ Therapeutics

LENZ stock →

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees

BDTX vs LENZ FAQ

Which is bigger, Black Diamond Therapeutics or LENZ Therapeutics?

LENZ Therapeutics (LENZ) is larger, with a market capitalization of $93.16M compared with $75.28M for Black Diamond Therapeutics (BDTX).

Which stock has performed better over the past year, BDTX or LENZ?

BDTX returned -65.53% over the past 12 months, compared with -89.97% for LENZ (price return, excluding dividends). Past performance does not predict future results.

Are Black Diamond Therapeutics and LENZ Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons